Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583501 · ClinicalTrials.gov registry record · Early Phase 1
Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT04583501: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT04583501 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04583501, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of this study is to examine the mechanism of action of omalizumab in ex vivo tissue culture of whole human nasal polyps from patients with chronic rhino sinusitis with nasal polyposis (CRSwNP), such that specific molecular markers of inflammation can be identified.
Interventions
- BIOLOGICAL Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2024-07-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04583501
The ClinicalTrials.gov registry entry for NCT04583501 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT04583501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04583501 about?
NCT04583501 is a clinical study titled "Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis". The goal of this study is to examine the mechanism of action of omalizumab in ex vivo tissue culture of whole human nasal polyps from patients with chronic rhino sinusitis with nasal polyposis (CRSwNP), such that specific molecular markers of inflammation can be identified.
What is the current status of trial NCT04583501?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2020-12-15. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT04583501?
The interventions under investigation include: Omalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04583501?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.